AXSM Axsome Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXSM

Price (delayed)

$235.49

Market cap

$12.12B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.72

Enterprise value

$12.03B

?
Relative Growth: Rel. Growth: 63
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 7
Relative Profitability: Rel. Profitability: 33

Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people ...

Highlights
AXSM's gross profit has surged by 66% year-on-year and by 11% since the previous quarter
The revenue has soared by 64% YoY and by 11% from the previous quarter
The equity has declined by 38% since the previous quarter but it has increased by 2.6% year-on-year
The net income has grown by 32% YoY but it has contracted by 2.8% from the previous quarter
The quick ratio has contracted by 33% YoY and by 12% from the previous quarter
Axsome Therapeutics's debt has increased by 3.5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.axsome.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of AXSM

AXSM stock price

How has the Axsome Therapeutics stock price performed over time
Intraday
0.86%
1 week
1.14%
1 month
5.27%
1 year
117.76%
YTD
28.94%
QTD
39.33%

Financial performance

How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$708.24M
Gross profit
$655.82M
Operating income
-$173.14M
Net income
-$188.3M
Gross margin
92.6%
Net margin
-26.6%
AXSM's gross profit has surged by 66% year-on-year and by 11% since the previous quarter
The revenue has soared by 64% YoY and by 11% from the previous quarter
AXSM's operating margin has soared by 61% year-on-year and by 7% since the previous quarter
Axsome Therapeutics's net margin has surged by 59% YoY and by 7% QoQ

Price vs fundamentals

How does AXSM's price correlate with its fundamentals

Growth

What is Axsome Therapeutics's growth rate over time

Valuation

What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
220.68
P/S
17.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.99
The EPS has grown by 36% YoY
The P/B is 111% higher than the last 4 quarters average of 103.8
The equity has declined by 38% since the previous quarter but it has increased by 2.6% year-on-year
The revenue has soared by 64% YoY and by 11% from the previous quarter
The price to sales (P/S) is 44% lower than the 5-year quarterly average of 30.1 but 42% higher than the last 4 quarters average of 11.9

Efficiency

How efficient is Axsome Therapeutics business performance
The ROS has soared by 59% YoY and by 6% from the previous quarter
AXSM's ROA is up by 43% YoY
The ROE has grown by 29% YoY but it has contracted by 2.3% from the previous quarter
The company's return on invested capital rose by 19% YoY but it fell by 16% QoQ

Dividends

What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXSM.

Financial health

How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 8% more than its total liabilities
The quick ratio has contracted by 33% YoY and by 12% from the previous quarter
AXSM's current ratio is down by 32% year-on-year and by 10% since the previous quarter
The debt to equity has soared by 63% QoQ
The equity has declined by 38% since the previous quarter but it has increased by 2.6% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.